

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
25 July 2002 (25.07.2002)

PCT

(10) International Publication Number
WO 02/057244 A1(51) International Patent Classification: C07D 279/28,
279/26, 417/04, 417/14, A61K 31/5415, A61P 35/00,
37/02(74) Agent: STEVENS, Lauren, L.; Beyer Weaver & Thomas,
LLP, 2030 Addison Street, 7th Floor, P.O. Box 778, Berke-
ley, CA 94704 (US).

(21) International Application Number: PCT/US02/01710

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(22) International Filing Date: 18 January 2002 (18.01.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/263,092 19 January 2001 (19.01.2001) US(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
TG).(71) Applicant (*for all designated States except US*): CY-
TOKINETICS, INC. [US/US]; 280 East Grand Avenue,
South San Francisco, CA 94080 (US).

(72) Inventors; and


(75) Inventors/Applicants (*for US only*): FINER, Jeffrey, T.
[US/US]; 661 Leo Drive, Foster City, CA 94404 (US).
CHABALA, John, C. [US/US]; 602 Sherwood Parkway,
Mountainside, NJ 07092 (US).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: PHENOTHIAZINE KINESIN INHIBITORS



(I)

(57) Abstract: Phenothiazine derivatives of formula (I) are
disclosed. The compounds are inhibitors of the mitotic ki-
nesin KSP and are useful in the treatment of cellular pro-
liferative diseases, such as cancer, hyperplasias, restenosis,
cardiac hypertrophy, immune disorders and inflammation.

PHENOTHIAZINE KINESIN INHIBITORS

RELATED APPLICATIONS

[0001] This application claims priority under 35 U.S.C. §119(e) to USSN 60/263,092, filed January 19, 2001, which is incorporated by reference in their entirety for all purposes.

FIELD OF THE INVENTION

[0002] This invention relates to phenothiazine derivatives which are inhibitors of the mitotic kinesin KSP and are useful in the treatment of cellular proliferative diseases, for example cancer, hyperplasias, restenosis, cardiac hypertrophy, immune disorders and inflammation.

BACKGROUND OF THE INVENTION

[0003] Among the therapeutic agents used to treat cancer are the taxanes and vinca alkaloids, which act on microtubules. Microtubules are the primary structural element of the mitotic spindle. The mitotic spindle is responsible for distribution of replicate copies of the genome to each of the two daughter cells that result from cell division. It is presumed that disruption of the mitotic spindle by these drugs results in inhibition of cancer cell division, and induction of cancer cell death. However, microtubules form other types of cellular structures, including tracks for intracellular transport in nerve processes. Because these agents do not specifically target mitotic spindles, they have side effects that limit their usefulness.

[0004] Improvements in the specificity of agents used to treat cancer is of considerable interest because of the therapeutic benefits which would be realized if the side effects associated with the administration of these agents could be reduced. Traditionally, dramatic improvements in the treatment of cancer are associated with identification of therapeutic agents acting through novel mechanisms. Examples of this include not only the taxanes, but also the camptothecin class of topoisomerase I inhibitors. From both of these perspectives, mitotic kinesins are attractive targets for new anti-cancer agents.

[0005] Mitotic kinesins are enzymes essential for assembly and function of the mitotic spindle, but are not generally part of other microtubule structures, such as in nerve processes. Mitotic kinesins play essential roles during all phases of mitosis. These

enzymes are "molecular motors" that transform energy released by hydrolysis of ATP into mechanical force which drives the directional movement of cellular cargoes along microtubules. The catalytic domain sufficient for this task is a compact structure of approximately 340 amino acids. During mitosis, kinesins organize microtubules into the bipolar structure that is the mitotic spindle. Kinesins mediate movement of chromosomes along spindle microtubules, as well as structural changes in the mitotic spindle associated with specific phases of mitosis. Experimental perturbation of mitotic kinesin function causes malformation or dysfunction of the mitotic spindle, frequently resulting in cell cycle arrest and cell death.

[0006] Among the mitotic kinesins which have been identified is KSP. KSP belongs to an evolutionarily conserved kinesin subfamily of plus end-directed microtubule motors that assemble into bipolar homotetramers consisting of antiparallel homodimers. During mitosis KSP associates with microtubules of the mitotic spindle. Microinjection of antibodies directed against KSP into human cells prevents spindle pole separation during prometaphase, giving rise to monopolar spindles and causing mitotic arrest and induction of programmed cell death. KSP and related kinesins in other, non-human, organisms, bundle antiparallel microtubules and slide them relative to one another, thus forcing the two spindle poles apart. KSP may also mediate in anaphase B spindle elongation and focussing of microtubules at the spindle pole.

[0007] Human KSP (also termed HsEg5) has been described (Blangy, et al., Cell, 83:1159-69 (1995); Whitehead, et al., Arthritis Rheum., 39:1635-42 (1996); Galgio et al., J. Cell Biol., 135:339-414 (1996); Blangy, et al., J Biol. Chem., 272:19418-24 (1997); Blangy, et al., Cell Motil Cytoskeleton, 40:174-82 (1998); Whitehead and Rattner, J. Cell Sci., 111:2551-61 (1998); Kaiser, et al., JBC 274:18925-31 (1999); GenBank accession numbers: X85137, NM004523 and U37426), and a fragment of the KSP gene (TRIP5) has been described (Lee, et al., Mol Endocrinol., 9:243-54 (1995); GenBank accession number L40372). Xenopus KSP homologs (Eg5), as well as Drosophila KLP61 F/KRP1 30 have been reported.

[0008] Mitotic kinesins are attractive targets for the discovery and development of novel mitotic chemotherapeutics. Accordingly, it is an object of the present invention to provide methods and compositions useful in the inhibition of KSP, a mitotic kinesin.


[0009] Phenothiazines have been known as psychopharmacologic agents for many years. Chlorpromazine, fluphenazine, perphenazine, trifluoperazine, promazine

and thioridazine are typical examples. Inhibition of KSP by phenothiazines has not been described.

SUMMARY OF THE INVENTION

[0010] In accordance with the objects outlined above, the present invention provides compositions and methods that can be used to treat diseases of proliferating cells. The compositions are KSP inhibitors, particularly human KSP inhibitors.

[0011] In one aspect, the invention relates to methods for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The methods employ compounds of the formula:



wherein

R¹ is hydrogen, halogen or CF₃;

R² is chosen from hydrogen and lower alkyl;

R³ is hydrogen;

R⁴ and R⁵ are independently chosen from hydrogen, alkyl, substituted alkyl, alkylaryl, substituted alkylaryl, alkylheteroaryl and substituted alkylheteroaryl; or any of R², R³ and R⁴ taken together with the intervening atoms form one or more five- to seven-membered rings, or a pharmaceutically acceptable salt thereof.

[0012] The ring may be substituted with one or more alkyl, aryl, alkoxy, halo, alkylaryl or substituted alkylaryl substituents. It is necessary for activity that the phenothiazine contain at least one five- to seven-membered ring in addition to the three rings of the phenothiazine.

[0013] Diseases and disorders that respond to therapy with compounds of the invention include cancer, hyperplasia, restenosis, cardiac hypertrophy, immune disorders and inflammation.

[0014] In another aspect, the invention relates to compounds useful in inhibiting KSP kinesin. The compounds have the structures shown above.

[0015] In an additional aspect, the present invention provides methods of screening for compounds that will bind to a KSP kinesin, for example compounds that will displace or compete with the binding of the compositions of the invention. The methods comprise combining a labeled compound of the invention, a KSP kinesin, and at least one candidate agent and determining the binding of the candidate bioactive agent to the KSP kinesin.


[0016] In a further aspect, the invention provides methods of screening for modulators of KSP kinesin activity. The methods comprise combining a composition of the invention, a KSP kinesin, and at least one candidate agent and determining the effect of the candidate bioactive agent on the KSP kinesin activity.

DETAILED DESCRIPTION OF THE INVENTION

[0017] The present invention is directed to a class of novel phenothiazines that are modulators of mitotic kinesins. By inhibiting or modulating mitotic kinesins, but not other kinesins (e.g., transport kinesins), specific inhibition of cellular proliferation is accomplished. Thus, the present invention capitalizes on the finding that perturbation of mitotic kinesin function causes malformation or dysfunction of mitotic spindles, frequently resulting in cell cycle arrest and cell death. The methods of inhibiting a human KSP kinesin comprise contacting an inhibitor of the invention with a KSP kinesin, particularly human KSP kinesins, including fragments and variants of KSP. The inhibition can be of the ATP hydrolysis activity of the KSP kinesin and/or the mitotic spindle formation activity, such that the mitotic spindles are disrupted. Meiotic spindles may also be disrupted.

[0018] An object of the present invention is to develop inhibitors and modulators of mitotic kinesins, in particular KSP, for the treatment of disorders associated with cell proliferation. Traditionally, dramatic improvements in the treatment of cancer, one type of cell proliferative disorder, have been associated with identification of therapeutic agents acting through novel mechanisms. Examples of this include not only the taxane class of agents that appear to act on microtubule formation, but also the camptothecin class of topoisomerase I inhibitors. The compositions and methods described herein can differ in their selectivity and are preferably used to treat diseases of proliferating cells, including, but not limited to cancer, hyperplasias, restenosis, cardiac hypertrophy, immune disorders and inflammation.

[0019] Accordingly, the present invention relates to methods employing phenothiazines of the formula:



wherein

R^1 is hydrogen, halogen or CF_3 ;


R^2 is chosen from hydrogen and lower alkyl;

R^3 is hydrogen;

R^4 and R^5 are independently chosen from hydrogen, alkyl, substituted alkyl, alkylaryl, substituted alkylaryl, alkylheteroaryl and substituted alkylheteroaryl; or

any of R^2 , R^3 and R^4 taken together with the intervening atoms form one or more five- to seven-membered rings that may be optionally substituted with one or more alkyl, aryl, alkoxy, halo, alkylaryl or substituted alkylaryl substituents, or a pharmaceutically acceptable salt thereof. It is necessary for activity that the phenothiazine contain at least one five- to seven-membered ring in addition to the three rings of the phenothiazine.

[0020] All of the compounds falling within the foregoing parent genus and its subgenera are useful as kinesin inhibitors, but not all the compounds are novel. In particular, certain known species fall within the genus in which R^4 and R^5 have the full breadth of operative substituents, although no utility in inhibiting kinesin has been suggested for these species. Any narrowing of the claims or specific exceptions that might be added to these claims reflect applicants' intent to avoid claiming subject matter that, while functionally part of the inventive concept, is not patentable to them for reasons having nothing to do with the scope of their invention. In particular, the novel compounds that are the subject of the claims are described by the formula:




wherein R^1 , R^2 and R^3 are as defined above;

R^{4a} is chosen from hydrogen and lower alkyl; and

R^{5a} is chosen from alkylaryl, substituted alkylaryl, alkylheteroaryl and substituted alkylheteroaryl; or

any of R^2 , R^3 and R^{4a} taken together with the intervening atoms form one or more five- to seven-membered rings, which may be optionally substituted with one or more alkyl, aryl, alkoxy, halo, alkylaryl or substituted alkylaryl substituents, or a pharmaceutically acceptable salt thereof.

[0021] Preferred compounds of the methods and compositions are those in which R^3 is hydrogen and R^2 and R^{4a} form a five- to seven-membered ring. Such compounds include phenothiazines of formula



[0022] In most preferred compounds R^{5a} is benzyl or substituted benzyl.

[0023] Other preferred compounds of the methods and compositions are those in which R^2 and R^3 are hydrogen and R^{5a} is alkylaryl or substituted alkylaryl, particularly those in which R^{5a} is benzyl or substituted benzyl.

Definitions

[0024] Alkyl is intended to include linear, branched, or cyclic hydrocarbon structures and combinations thereof. Lower alkyl refers to alkyl groups of from 1 to 5 carbon atoms. Examples of lower alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, s- and t-butyl and the like. Preferred alkyl groups are those of C_{20} or below. More preferred alkyl groups are those of C_{13} or below. Cycloalkyl is a subset of alkyl and includes cyclic hydrocarbon groups of from 3 to 13 carbon atoms. Examples of cycloalkyl groups include c-propyl, c-butyl, c-pentyl, norbornyl, adamantyl and the like. In this application, alkyl refers to alkanyl, alkenyl and alkynyl residues; it is intended to include cyclohexylmethyl, vinyl, allyl, isoprenyl and the like. Alkylene refers to the same residues as alkyl, but having two points of attachment. Examples of alkylene include ethylene ($-CH_2CH_2-$), propylene ($-CH_2CH_2CH_2-$), dimethylpropylene ($-CH_2C(CH_3)_2CH_2-$) and cyclohexylpropylene ($-CH_2CH_2CH(C_6H_{13})-$). When an alkyl residue having a specific number of carbons is named, all geometric isomers having that number of carbons are intended to be encompassed; thus, for example, "butyl" is meant to include n-butyl, sec-butyl, isobutyl and t-butyl; "propyl" includes n-propyl and isopropyl.

[0025] Alkoxy or alkoxyl refers to groups of from 1 to 8 carbon atoms of a straight, branched, cyclic configuration and combinations thereof attached to the parent structure through an oxygen. Examples include methoxy, ethoxy, propoxy, isopropoxy, cyclopropyloxy, cyclohexyloxy and the like. Lower-alkoxy refers to groups containing one to four carbons.

[0026] Acyl refers to groups of from 1 to 8 carbon atoms of a straight, branched, cyclic configuration, saturated, unsaturated and aromatic and combinations thereof, attached to the parent structure through a carbonyl functionality. One or more carbons in the acyl residue may be replaced by nitrogen, oxygen or sulfur as long as the point of attachment to the parent remains at the carbonyl. Examples include acetyl, benzoyl, propionyl, isobutyryl, t-butoxycarbonyl, benzyloxycarbonyl and the like. Lower-acyl refers to groups containing one to four carbons.

[0027] Aryl and heteroaryl mean a 5- or 6-membered aromatic or heteroaromatic ring containing 0-3 heteroatoms selected from O, N, or S; a bicyclic 9- or 10-membered aromatic or heteroaromatic ring system containing 0-3 heteroatoms selected from O, N,

or S; or a tricyclic 13- or 14-membered aromatic or heteroaromatic ring system containing 0-3 heteroatoms selected from O, N, or S. The aromatic 6- to 14-membered carbocyclic rings include, e.g., benzene, naphthalene, indane, tetralin, and fluorene and the 5- to 10-membered aromatic heterocyclic rings include, e.g., imidazole, pyridine, indole, thiophene, benzopyranone, thiazole, furan, benzimidazole, quinoline, isoquinoline, quinoxaline, pyrimidine, pyrazine, tetrazole and pyrazole.

[0028] Alkylaryl refers to a residue in which an aryl moiety is attached to the parent structure via an alkyl residue. Examples are benzyl, phenethyl, phenylvinyl, phenylallyl and the like. Alkylheteroaryl refers to a residue in which a heteroaryl moiety is attached to the parent structure via an alkyl residue. Examples include furanylmethyl, pyridinylmethyl, pyrimidinylethyl and the like.

[0029] Heterocycle means a cycloalkyl or aryl residue in which one to four of the carbons is replaced by a heteroatom such as oxygen, nitrogen or sulfur. Examples of heterocycles that fall within the scope of the invention include imidazoline, pyrrolidine, pyrazole, pyrrole, indole, quinoline, isoquinoline, tetrahydroisoquinoline, benzofuran, benzodioxan, benzodioxole (commonly referred to as methylenedioxyphenyl, when occurring as a substituent), tetrazole, morpholine, thiazole, pyridine, pyridazine, pyrimidine, thiophene, furan, oxazole, oxazoline, isoxazole, dioxane, tetrahydrofuran and the like. Examples of substituted heterocyclyl include 4-methyl-1-piperazinyl and 4-benzyl-1-piperidinyl.

[0030] Substituted alkyl, aryl and heteroaryl or heterocyclyl refer to alkyl, aryl, heteroaryl or heterocyclyl wherein H atoms are replaced with alkyl, halogen, hydroxy, alkoxy, alkylenedioxy (e.g. methylenedioxy) fluoroalkyl, carboxy (-COOH), carboalkoxy (i.e. acyloxy RCOO-), carboxyalkyl (-COOR), carboxamido, sulfonamidoalkyl, sulfonamidoaryl, aminocarbonyl, benzyloxycarbonylamino (CBZ-amino), cyano, carbonyl, nitro, dialkylamino, alkylamino, amino, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylsulfonamido, arylthio, arylsulfinyl, arylsulfonyl, amidino, phenyl, benzyl, heteroaryl, heterocyclyl, phenoxy, benzyloxy, or heteroaryloxy. For the purposes of the present invention, substituted alkyl also includes oxaalkyl residues, i.e. alkyl residues in which one or more carbons has been replaced by oxygen.

[0031] Halogen refers to fluorine, chlorine, bromine or iodine. Fluorine, chlorine and bromine are preferred.

[0032] Many of the compounds described herein contain one or more asymmetric centers (e.g. the carbons to which R^2 and R^3 are attached) and may thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that may be defined, in terms of absolute stereochemistry, as (R)- or (S)-. The present invention is meant to include all such possible isomers, including racemic mixtures, optically pure forms and intermediate mixtures. Optically active (R)- and (S)- isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques. When the compounds described herein contain olefinic double bonds or other centers of geometric asymmetry, and unless specified otherwise, it is intended that the compounds include both E and Z geometric isomers. Likewise, all tautomeric forms are also intended to be included.

[0033] When desired, the R- and S-isomers may be resolved by methods known to those skilled in the art, for example by formation of diastereoisomeric salts or complexes which may be separated, for example, by crystallisation; via formation of diastereoisomeric derivatives which may be separated, for example, by crystallisation, gas-liquid or liquid chromatography; selective reaction of one enantiomer with an enantiomer-specific reagent, for example enzymatic oxidation or reduction, followed by separation of the modified and unmodified enantiomers; or gas-liquid or liquid chromatography in a chiral environment, for example on a chiral support, such as silica with a bound chiral ligand or in the presence of a chiral solvent. It will be appreciated that where the desired enantiomer is converted into another chemical entity by one of the separation procedures described above, a further step may be required to liberate the desired enantiomeric form. Alternatively, specific enantiomer may be synthesized by asymmetric synthesis using optically active reagents, substrates, catalysts or solvents, or by converting one enantiomer to the other by asymmetric transformation.

[0034] The graphic representations of racemic, ambiscalemic and scalemic or enantiomerically pure compounds used herein are taken from Maehr J. Chem. Ed. 62, 114-120 (1985): solid and broken wedges are used to denote the absolute configuration of a chiral element; wavy lines indicate disavowal of any stereochemical implication which the bond it represents could generate; solid and broken bold lines are geometric descriptors indicating the relative configuration shown but denoting racemic character; and wedge outlines and dotted or broken lines denote enantiomerically pure compounds of indeterminate absolute configuration.

[0035] In some embodiments, two R groups may be joined to form a ring structure. Again, the ring structure may contain heteroatoms and may be substituted with one or more substituents.

[0036] The compositions of the invention are synthesized as outlined below, utilizing techniques well known in the art. Once made, the compositions of the invention find use in a variety of applications. As will be appreciated by those in the art, mitosis may be altered in a variety of ways; that is, one can affect mitosis either by increasing or decreasing the activity of a component in the mitotic pathway. Stated differently, mitosis may be affected (e.g., disrupted) by disturbing equilibrium, either by inhibiting or activating certain components. Similar approaches may be used to alter meiosis.

[0037] In a preferred embodiment, the compositions of the invention are used to modulate mitotic spindle formation, thus causing prolonged cell cycle arrest in mitosis. By "modulate" herein is meant altering mitotic spindle formation, including increasing and decreasing spindle formation. By "mitotic spindle formation" herein is meant organization of microtubules into bipolar structures by mitotic kinesins. By "mitotic spindle dysfunction" herein is meant mitotic arrest and monopolar spindle formation.

[0038] The compositions of the invention are useful to bind to and/or modulate the activity of a mitotic kinesin, KSP. In a preferred embodiment, the KSP is human KSP, although KSP kinesins from other organisms may also be used. In this context, modulate means either increasing or decreasing spindle pole separation, causing malformation, i.e., splaying, of mitotic spindle poles, or otherwise causing morphological perturbation of the mitotic spindle. Also included within the definition of KSP for these purposes are variants and/or fragments of KSP. See U.S. Patent Application "Methods of Screening for Modulators of Cell Proliferation and Methods of Diagnosing Cell Proliferation States", filed Oct. 27, 1999 (U.S. Serial Number 09/428,156), hereby incorporated by reference in its entirety. In addition, other mitotic kinesins may be used in the present invention. However, the compositions of the invention have been shown to have specificity for KSP.

[0039] For assay of activity, generally either KSP or a compound according to the invention is non-diffusably bound to an insoluble support having isolated sample receiving areas (e.g., a microtiter plate, an array, etc.). The insoluble support may be made of any composition to which the compositions can be bound, is readily separated from soluble material, and is otherwise compatible with the overall method of screening.

The surface of such supports may be solid or porous and of any convenient shape. Examples of suitable insoluble supports include microtiter plates, arrays, membranes and beads. These are typically made of glass, plastic (e.g., polystyrene), polysaccharides, nylon or nitrocellulose, Teflon™, etc. Microtiter plates and arrays are especially convenient because a large number of assays can be carried out simultaneously, using small amounts of reagents and samples. The particular manner of binding of the composition is not crucial so long as it is compatible with the reagents and overall methods of the invention, maintains the activity of the composition and is nondiffusible. Preferred methods of binding include the use of antibodies (which do not sterically block either the ligand binding site or activation sequence when the protein is bound to the support), direct binding to "sticky" or ionic supports, chemical crosslinking, the synthesis of the protein or agent on the surface, etc. Following binding of the protein or agent, excess unbound material is removed by washing. The sample receiving areas may then be blocked through incubation with bovine serum albumin (BSA), casein or other innocuous protein or other moiety.

[0040] The antimitotic agents of the invention may be used on their own to modulate the activity of a mitotic kinesin, particularly KSP. In this embodiment, the mitotic agents of the invention are combined with KSP and the activity of KSP is assayed. Kinesin activity is known in the art and includes one or more kinesin activities. Kinesin activities include the ability to affect ATP hydrolysis; microtubule binding; gliding and polymerization/depolymerization (effects on microtubule dynamics); binding to other proteins of the spindle; binding to proteins involved in cell-cycle control; serving as a substrate to other enzymes; such as kinases or proteases; and specific kinesin cellular activities such as spindle pole separation.

[0041] Methods of performing motility assays are well known to those of skill in the art. (See e.g., Hall, et al. (1996), *Biophys. J.*, 71: 3467-3476, Turner et al., 1996, *Anal. Biochem.* 242 (1):20-5; Gittes et al., 1996, *Biophys. J.* 70(1): 418-29; Shirakawa et al., 1995, *J. Exp. Biol.* 198: 1809-15; Winkelmann et al., 1995, *Biophys. J.* 68: 2444-53; Winkelmann et al., 1995, *Biophys. J.* 68: 72S.)

[0042] Methods known in the art for determining ATPase hydrolysis activity also can be used. Preferably, solution based assays are utilized. U.S. application 09/314,464, filed May 18, 1999, hereby incorporated by reference in its entirety, describes such assays. Alternatively, conventional methods are used. For example, P_i

release from kinesin can be quantified. In one preferred embodiment, the ATPase hydrolysis activity assay utilizes 0.3 M PCA (perchloric acid) and malachite green reagent (8.27 mM sodium molybdate II, 0.33 mM malachite green oxalate, and 0.8 mM Triton X-100). To perform the assay, 10 μ L of reaction is quenched in 90 μ L of cold 0.3 M PCA. Phosphate standards are used so data can be converted to mM inorganic phosphate released. When all reactions and standards have been quenched in PCA, 100 μ L of malachite green reagent is added to the relevant wells in e.g., a microtiter plate. The mixture is developed for 10-15 minutes and the plate is read at an absorbance of 650 nm. If phosphate standards were used, absorbance readings can be converted to mM P_i and plotted over time. Additionally, ATPase assays known in the art include the luciferase assay.

[0043] ATPase activity of kinesin motor domains also can be used to monitor the effects of modulating agents. In one embodiment ATPase assays of kinesin are performed in the absence of microtubules. In another embodiment, the ATPase assays are performed in the presence of microtubules. Different types of modulating agents can be detected in the above assays. In a preferred embodiment, the effect of a modulating agent is independent of the concentration of microtubules and ATP. In another embodiment, the effect of the agents on kinesin ATPase can be decreased by increasing the concentrations of ATP, microtubules or both. In yet another embodiment, the effect of the modulating agent is increased by increasing concentrations of ATP, microtubules or both.

[0044] Agents that modulate the biochemical activity of KSP in vitro may then be screened in vivo. Methods for such agents in vivo include assays of cell cycle distribution, cell viability, or the presence, morphology, activity, distribution, or amount of mitotic spindles. Methods for monitoring cell cycle distribution of a cell population, for example, by flow cytometry, are well known to those skilled in the art, as are methods for determining cell viability. See for example, U.S. Patent Application "Methods of Screening for Modulators of Cell Proliferation and Methods of Diagnosing Cell Proliferation States," filed Oct. 22, 1999, serial number 09/428,156, hereby incorporated by reference in its entirety.

[0045] In addition to the assays described above, microscopic methods for monitoring spindle formation and malformation are well known to those of skill in the

art (see, e.g., Whitehead and Rattner (1998), J. Cell Sci. 111:2551-61; Galgio et al, (1996) J. Cell biol., 135:399-414).

[0046] The compositions of the invention inhibit the KSP kinesin. One measure of inhibition is IC_{50} , defined as the concentration of the composition at which the activity of KSP is decreased by fifty percent. Preferred compositions have IC_{50} 's of less than about 1 mM, with preferred embodiments having IC_{50} 's of less than about 100 μ M, with more preferred embodiments having IC_{50} 's of less than about 10 μ M, with particularly preferred embodiments having IC_{50} 's of less than about 1 μ M, and especially preferred embodiments having IC_{50} 's of less than about 500 nM. Measurement of IC_{50} is done using an ATPase assay.

[0047] Another measure of inhibition is K_i . For compounds with IC_{50} 's less than 1 μ M, the K_i or K_d is defined as the dissociation rate constant for the interaction of the phenothiazine with KSP. Preferred compounds have K_i 's of less than about 100 μ M, with preferred embodiments having K_i 's of less than about 10 μ M, and particularly preferred embodiments having K_i 's of less than about 1 μ M and especially preferred embodiments having K_i 's of less than about 500 nM.

[0048] Another measure of inhibition is GI_{50} , defined as the concentration of the compound that results in a decrease in the rate of cell growth by fifty percent. Preferred compounds have GI_{50} 's of less than about 1 mM. The level of preferability of embodiments is a function of their GI_{50} : those having GI_{50} 's of less than about 20 μ M are more preferred; those having GI_{50} 's of 10 μ M more so; those having GI_{50} of less than about 1 μ M more so; those having GI_{50} 's of 500 nM more so. Measurement of GI_{50} is done using a cell proliferation assay.

[0049] The compositions of the invention are used to treat cellular proliferation diseases. Disease states which can be treated by the methods and compositions provided herein include, but are not limited to, cancer (further discussed below), autoimmune disease, arthritis, graft rejection, inflammatory bowel disease, proliferation induced after medical procedures, including, but not limited to, surgery, angioplasty, and the like. It is appreciated that in some cases the cells may not be in a hyper or hypo proliferation state (abnormal state) and still require treatment. For example, during wound healing, the cells may be proliferating "normally", but proliferation enhancement may be desired. Similarly, as discussed above, in the agriculture arena, cells may be in a "normal" state,

but proliferation modulation may be desired to enhance a crop by directly enhancing growth of a crop, or by inhibiting the growth of a plant or organism which adversely affects the crop. Thus, in one embodiment, the invention herein includes application to cells or individuals afflicted or impending affliction with any one of these disorders or states.

[0050] The compositions and methods provided herein are particularly deemed useful for the treatment of cancer including solid tumors such as skin, breast, brain, cervical carcinomas, testicular carcinomas, etc. More particularly, cancers that may be treated by the compositions and methods of the invention include, but are not limited to: Cardiac: sarcoma (angiosarcoma, fibrosarcoma, rhabdomyosarcoma, liposarcoma), myxoma, rhabdomyoma, fibroma, lipoma and teratoma; Lung: bronchogenic carcinoma (squamous cell, undifferentiated small cell, undifferentiated large cell, adenocarcinoma), alveolar (bronchiolar) carcinoma, bronchial adenoma, sarcoma, lymphoma, chondromatous hamartoma, mesothelioma; Gastrointestinal: esophagus (squamous cell carcinoma, adenocarcinoma, leiomyosarcoma, lymphoma), stomach (carcinoma, lymphoma, leiomyosarcoma), pancreas (ductal adenocarcinoma, insulinoma, glucagonoma, gastrinoma, carcinoid tumors, vipoma), small bowel (adenocarcinoma, lymphoma, carcinoid tumors, Kaposi's sarcoma, leiomyoma, hemangioma, lipoma, neurofibroma, fibroma), large bowel (adenocarcinoma, tubular adenoma, villous adenoma, hamartoma, leiomyoma); Genitourinary tract: kidney (adenocarcinoma, Wilm's tumor (nephroblastoma), lymphoma, leukemia), bladder and urethra (squamous cell carcinoma, transitional cell carcinoma, adenocarcinoma), prostate (adenocarcinoma, sarcoma), testis (seminoma, teratoma, embryonal carcinoma, teratocarcinoma, choriocarcinoma, sarcoma, interstitial cell carcinoma, fibroma, fibroadenoma, adenomatoid tumors, lipoma); Liver: hepatoma (hepatocellular carcinoma), cholangiocarcinoma, hepatoblastoma, angiosarcoma, hepatocellular adenoma, hemangioma; Bone: osteogenic sarcoma (osteosarcoma), fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma (reticulum cell sarcoma), multiple myeloma, malignant giant cell tumor chordoma, osteochondroma (osteochondrogenous exostoses), benign chondroma, chondroblastoma, chondromyxofibroma, osteoid osteoma and giant cell tumors; Nervous system: skull (osteoma, hemangioma, granuloma, xanthoma, osteitis deformans), meninges (meningioma, meningiosarcoma, gliomatosis), brain (astrocytoma, medulloblastoma,

glioma, ependymoma, germinoma (pinealoma), glioblastoma multiform, oligodendroglioma, schwannoma, retinoblastoma, congenital tumors), spinal cord neurofibroma, meningioma, glioma, sarcoma); Gynecological: uterus (endometrial carcinoma), cervix (cervical carcinoma, pre-tumor cervical dysplasia), ovaries (ovarian carcinoma (serous cystadenocarcinoma, mucinous cystadenocarcinoma, unclassified carcinoma), granulosa-thecal cell tumors, Sertoli-Leydig cell tumors, dysgerminoma, malignant teratoma), vulva (squamous cell carcinoma, intraepithelial carcinoma, adenocarcinoma, fibrosarcoma, melanoma), vagina (clear cell carcinoma, squamous cell carcinoma, botryoid sarcoma (embryonal rhabdomyosarcoma), fallopian tubes (carcinoma); Hematologic: blood (myeloid leukemia (acute and chronic), acute lymphoblastic leukemia, chronic lymphocytic leukemia, myeloproliferative diseases, multiple myeloma, myelodysplastic syndrome), Hodgkin's disease, non-Hodgkin's lymphoma (malignant lymphoma); Skin: malignant melanoma, basal cell carcinoma, squamous cell carcinoma, Kaposi's sarcoma, moles dysplastic nevi, lipoma, angioma, dermatofibroma, keloids, psoriasis; and Adrenal glands: neuroblastoma. Thus, the term "cancerous cell" as provided herein, includes a cell afflicted by any one of the above identified conditions.

[0051] Accordingly, the compositions of the invention are administered to cells. By "administered" herein is meant administration of a therapeutically effective dose of the mitotic agents of the invention to a cell either in cell culture or in a patient. By "therapeutically effective dose" herein is meant a dose that produces the effects for which it is administered. The exact dose will depend on the purpose of the treatment, and will be ascertainable by one skilled in the art using known techniques. As is known in the art, adjustments for systemic versus localized delivery, age, body weight, general health, sex, diet, time of administration, drug interaction and the severity of the condition may be necessary, and will be ascertainable with routine experimentation by those skilled in the art. By "cells" herein is meant cells in which mitosis or meiosis can be altered.

[0052] A "patient" for the purposes of the present invention includes both humans and other animals, particularly mammals, and other organisms. Thus the methods are applicable to both human therapy and veterinary applications. In the preferred embodiment the patient is a mammal, and in the most preferred embodiment the patient is human.

[0053] Mitotic agents having the desired pharmacological activity may be administered in a physiologically acceptable carrier to a patient, as described herein. Depending upon the manner of introduction, the compounds may be formulated in a variety of ways as discussed below. The concentration of therapeutically active compound in the formulation may vary from about 0.1-100 wt.%. The agents may be administered alone or in combination with other treatments, i.e., radiation, or other chemotherapeutic agents.

[0054] In a preferred embodiment, the pharmaceutical compositions are in a water soluble form, such as pharmaceutically acceptable salts, which is meant to include both acid and base addition salts. "Pharmaceutically acceptable acid addition salt" refers to those salts that retain the biological effectiveness of the free bases and that are not biologically or otherwise undesirable, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, and organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid and the like. "Pharmaceutically acceptable base addition salts" include those derived from inorganic bases such as sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like. Particularly preferred are the ammonium, potassium, sodium, calcium, and magnesium salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, and ethanolamine.

[0055] The pharmaceutical compositions can be prepared in various forms, such as granules, tablets, pills, suppositories, capsules, suspensions, salves, lotions and the like. Pharmaceutical grade organic or inorganic carriers and/or diluents suitable for oral and topical use can be used to make up compositions containing the therapeutically-active compounds. Diluents known to the art include aqueous media, vegetable and animal oils and fats. Stabilizing agents, wetting and emulsifying agents, salts for varying the osmotic pressure or buffers for securing an adequate pH value, and skin penetration enhancers can be used as auxiliary agents. The pharmaceutical compositions may also

include one or more of the following: carrier proteins such as serum albumin; buffers; fillers such as microcrystalline cellulose, lactose, corn and other starches; binding agents; sweeteners and other flavoring agents; coloring agents; and polyethylene glycol.

Additives are well known in the art, and are used in a variety of formulations.

[0056] The administration of the mitotic agents of the present invention can be done in a variety of ways as discussed above, including, but not limited to, orally, subcutaneously, intravenously, intranasally, transdermally, intraperitoneally, intramuscularly, intrapulmonary, vaginally, rectally, or intraocularly. In some instances, for example, in the treatment of wounds and inflammation, the anti-mitotic agents may be directly applied as a solution or spray.

[0057] To employ the compounds of the invention in a method of screening for compounds that bind to KSP kinesin, the KSP is bound to a support, and a compound of the invention (which is a mitotic agent) is added to the assay. Alternatively, the compound of the invention is bound to the support and KSP is added. Classes of compounds among which novel binding agents may be sought include specific antibodies, non-natural binding agents identified in screens of chemical libraries, peptide analogs, etc. Of particular interest are screening assays for candidate agents that have a low toxicity for human cells. A wide variety of assays may be used for this purpose, including labeled in vitro protein-protein binding assays, electrophoretic mobility shift assays, immunoassays for protein binding, functional assays (phosphorylation assays, etc.) and the like.

[0058] The determination of the binding of the mitotic agent to KSP may be done in a number of ways. In a preferred embodiment, the mitotic agent (the compound of the invention) is labeled, for example, with a fluorescent or radioactive moiety and binding determined directly. For example, this may be done by attaching all or a portion of KSP to a solid support, adding a labeled mitotic agent (for example a compound of the invention in which at least one atom has been replaced by a detectable isotope), washing off excess reagent, and determining whether the amount of the label is that present on the solid support. Various blocking and washing steps may be utilized as is known in the art.

[0059] By "labeled" herein is meant that the compound is either directly or indirectly labeled with a label which provides a detectable signal, e.g., radioisotope, fluorescent tag, enzyme, antibodies, particles such as magnetic particles,

chemiluminescent tag, or specific binding molecules, etc. Specific binding molecules include pairs, such as biotin and streptavidin, digoxin and antidigoxin etc. For the specific binding members, the complementary member would normally be labeled with a molecule which provides for detection, in accordance with known procedures, as outlined above. The label can directly or indirectly provide a detectable signal.

[0060] In some embodiments, only one of the components is labeled. For example, the kinesin proteins may be labeled at tyrosine positions using ^{125}I , or with fluorophores. Alternatively, more than one component may be labeled with different labels; using ^{125}I for the proteins, for example, and a fluorophor for the mitotic agents.

[0061] The compounds of the invention may also be used as competitors to screen for additional drug candidates. "Candidate bioactive agent" or "drug candidate" or grammatical equivalents as used herein describe any molecule, e.g., protein, oligopeptide, small organic molecule, polysaccharide, polynucleotide, etc., to be tested for bioactivity. They may be capable of directly or indirectly altering the cellular proliferation phenotype or the expression of a cellular proliferation sequence, including both nucleic acid sequences and protein sequences. In other cases, alteration of cellular proliferation protein binding and/or activity is screened. Screens of this sort may be performed either in the presence or absence of microtubules. In the case where protein binding or activity is screened, preferred embodiments exclude molecules already known to bind to that particular protein, for example, polymer structures such as microtubules, and energy sources such as ATP. Preferred embodiments of assays herein include candidate agents which do not bind the cellular proliferation protein in its endogenous native state termed herein as "exogenous" agents. In another preferred embodiment, exogenous agents further exclude antibodies to KSP.

[0062] Candidate agents can encompass numerous chemical classes, though typically they are organic molecules, preferably small organic compounds having a molecular weight of more than 100 and less than about 2,500 daltons. Candidate agents comprise functional groups necessary for structural interaction with proteins, particularly hydrogen bonding and lipophilic binding, and typically include at least an amine, carbonyl, hydroxyl, ether, or carboxyl group, preferably at least two of the functional chemical groups. The candidate agents often comprise cyclical carbon or heterocyclic structures and/or aromatic or polyaromatic structures substituted with one or more of the above functional groups. Candidate agents are also found among biomolecules including

peptides, saccharides, fatty acids, steroids, purines, pyrimidines, derivatives, structural analogs or combinations thereof. Particularly preferred are peptides.

[0063] Candidate agents are obtained from a wide variety of sources including libraries of synthetic or natural compounds. For example, numerous means are available for random and directed synthesis of a wide variety of organic compounds and biomolecules, including expression of randomized oligonucleotides. Alternatively, libraries of natural compounds in the form of bacterial, fungal, plant and animal extracts are available or readily produced. Additionally, natural or synthetically produced libraries and compounds are readily modified through conventional chemical, physical and biochemical means. Known pharmacological agents may be subjected to directed or random chemical modifications, such as acylation, alkylation, esterification, amidification to produce structural analogs.

[0064] Competitive screening assays may be done by combining KSP and a drug candidate in a first sample. A second sample comprises a mitotic agent, KSP and a drug candidate. This may be performed in either the presence or absence of microtubules. The binding of the drug candidate is determined for both samples, and a change, or difference in binding between the two samples indicates the presence of an agent capable of binding to KSP and potentially modulating its activity. That is, if the binding of the drug candidate is different in the second sample relative to the first sample, the drug candidate is capable of binding to KSP.

[0065] In a preferred embodiment, the binding of the candidate agent is determined through the use of competitive binding assays. In this embodiment, the competitor is a binding moiety known to bind to KSP, such as an antibody, peptide, binding partner, ligand, etc. Under certain circumstances, there may be competitive binding as between the candidate agent and the binding moiety, with the binding moiety displacing the candidate agent.

[0066] In one embodiment, the candidate agent is labeled. Either the candidate agent, or the competitor, or both, is added first to KSP for a time sufficient to allow binding, if present. Incubations may be performed at any temperature which facilitates optimal activity, typically between 4 and 40°C.

[0067] Incubation periods are selected for optimum activity, but may also be optimized to facilitate rapid high throughput screening. Typically between 0.1 and 1 hour will be sufficient. Excess reagent is generally removed or washed away. The

second component is then added, and the presence or absence of the labeled component is followed, to indicate binding.

[0068] In a preferred embodiment, the competitor is added first, followed by the candidate agent. Displacement of the competitor is an indication the candidate agent is binding to KSP and thus is capable of binding to, and potentially modulating, the activity of KSP. In this embodiment, either component can be labeled. Thus, for example, if the competitor is labeled, the presence of label in the wash solution indicates displacement by the agent. Alternatively, if the candidate agent is labeled, the presence of the label on the support indicates displacement.

[0069] In an alternative embodiment, the candidate agent is added first, with incubation and washing, followed by the competitor. The absence of binding by the competitor may indicate the candidate agent is bound to KSP with a higher affinity. Thus, if the candidate agent is labeled, the presence of the label on the support, coupled with a lack of competitor binding, may indicate the candidate agent is capable of binding to KSP.

[0070] It may be of value to identify the binding site of KSP. This can be done in a variety of ways. In one embodiment, once KSP has been identified as binding to the mitotic agent, KSP is fragmented or modified and the assays repeated to identify the necessary components for binding.

[0071] Modulation is tested by screening for candidate agents capable of modulating the activity of KSP comprising the steps of combining a candidate agent with KSP, as above, and determining an alteration in the biological activity of KSP. Thus, in this embodiment, the candidate agent should both bind to KSP (although this may not be necessary), and alter its biological or biochemical activity as defined herein. The methods include both in vitro screening methods and in vivo screening of cells for alterations in cell cycle distribution, cell viability, or for the presence, morphology, activity, distribution, or amount of mitotic spindles, as are generally outlined above.

[0072] Alternatively, differential screening may be used to identify drug candidates that bind to the native KSP, but cannot bind to modified KSP.

[0073] Positive controls and negative controls may be used in the assays. Preferably all control and test samples are performed in at least triplicate to obtain statistically significant results. Incubation of all samples is for a time sufficient for the binding of the agent to the protein. Following incubation, all samples are washed free of

non-specifically bound material and the amount of bound, generally labeled agent determined. For example, where a radiolabel is employed, the samples may be counted in a scintillation counter to determine the amount of bound compound.

[0074] A variety of other reagents may be included in the screening assays. These include reagents like salts, neutral proteins, e.g., albumin, detergents, etc which may be used to facilitate optimal protein-protein binding and/or reduce non-specific or background interactions. Also reagents that otherwise improve the efficiency of the assay, such as protease inhibitors, nuclease inhibitors, anti-microbial agents, etc., may be used. The mixture of components may be added in any order that provides for the requisite binding.

[0075] The following examples serve to more fully describe the manner of using the above-described invention, as well as to set forth the best modes contemplated for carrying out various aspects of the invention. It is understood that these examples in no way serve to limit the true scope of this invention, but rather are presented for illustrative purposes. All references cited herein are incorporated by reference in their entirety.

EXAMPLES

Abbreviations and Definitions

[0076] The following abbreviations and terms have the indicated meanings throughout:

Ac	=	acetyl
BNB	=	4-bromomethyl-3-nitrobenzoic acid
Boc	=	t-butyloxy carbonyl
Bu	=	butyl
c-	=	cyclo
CBZ	=	carbobenzoxy = benzyloxycarbonyl
DBU	=	diazabicyclo[5.4.0]undec-7-ene
DCM	=	dichloromethane = methylene chloride = CH_2Cl_2
DCE	=	dichloroethane
DEAD	=	diethyl azodicarboxylate
DIC	=	diisopropylcarbodiimide
DIEA	=	N,N-diisopropylethylamine
DMAP	=	4-N,N-dimethylaminopyridine
DMF	=	N,N-dimethylformamide
DMSO	=	dimethyl sulfoxide
DVB	=	1,4-divinylbenzene
EDCI	=	1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride
EEDQ	=	2-ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline
Et	=	ethyl
Fmoc	=	9-fluorenylmethoxycarbonyl
GC	=	gas chromatography
HATU	=	O-(7-Azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate
HMDS	=	hexamethyldisilazane
HOAc	=	acetic acid
HOBt	=	hydroxybenzotriazole
Me	=	methyl
mesyl	=	methanesulfonyl


MTBE	=	methyl t-butyl ether
NMO	=	N-methylmorpholine oxide
PEG	=	polyethylene glycol
Ph	=	phenyl
PhOH	=	phenol
PfP	=	pentafluorophenol
PPTS	=	pyridinium p-toluenesulfonate
Py	=	pyridine
PyBroP	=	bromo-tris-pyrrolidino-phosphonium hexafluorophosphate
rt	=	room temperature
sat=d	=	saturated
s-	=	secondary
t-	=	tertiary
TBDMS	=	t-butyldimethylsilyl
TES	=	triethylsilane
TFA	=	trifluoroacetic acid
THF	=	tetrahydrofuran
TMOF	=	trimethyl orthoformate
TMS	=	trimethylsilyl
tosyl	=	p-toluenesulfonyl
Trt	=	triphenylmethyl

Synthesis of Compounds





[0077] The syntheses of several prototypical phenothiazines are shown below.

Other phenothiazines are made in analogous fashion:

Phenothiazine Synthesis - Procedure A




Phenothiazine Synthesis - Procedure B



Phenothiazine Procedure A

[0078] Synthesis of Benzyl-[2-(2-chloro-phenothiazin-10-yl)-ethyl]-methylaniline fumarate.

**Synthesis of (2-chlorophenothiazin-10-yl)acetic acid.**

[0079] 2-Chloro-10H-phenothiazine (10.0 g, 42.8 mmol) was dissolved in THF (100 mL) and DMSO (10 mL). Sodium hydride (1.0 g, 43.4 mmol) was added, and the mixture was heated to reflux until gas evolution ceased. Ethyl bromoacetate (10 g, 59.9 mmol) was added slowly via syringe. The mixture was heated at reflux for 12 h. Sodium hydride (1.0 g, 43.4 mmol) and ethyl bromoacetate (5 g, 29.9 mmol) were added, and the mixture was heated an additional 12 h. The mixture was cooled to room temperature and carefully diluted with water followed by ethyl acetate. The layers were separated, and the aqueous layer extracted with ethyl acetate. The organic layers were combined, dried (Na_2SO_4), filtered, and concentrated to give a dark purple oil (11.8 g). The oil was dissolved in methanol (300 mL), and aqueous sodium hydroxide (6 N, 22 mL, 132 mmol) was added. The mixture was heated to reflux for 4 h. The mixture was cooled to room temperature, and the solvent removed under vacuum. The residue was dissolved in water and was extracted with diethyl ether (ether layers discarded). The layers were separated, and the pH of the aqueous layer was made acidic with concentrated hydrochloric acid. The water layer was extracted with methylene chloride. The organic layers were combined, dried (Na_2SO_4), filtered, and concentrated to give (2-chlorophenothiazin-10-yl)acetic acid (7.38 g, 56%) as a brown solid.

Synthesis of N-Benzyl-2-(2-chlorophenothiazin-10-yl)-N-methylacetamide

[0080] (2-Chlorophenothiazin-10-yl)acetic acid (480 mg, 1.65 mmol) was dissolved in THF (10 mL). To this solution, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (1.58 g, 8.25 mmol), 1-hydroxybenzotriazole (220 mg,


1.65 mmol), and *N*-methyl benzyl amine (2.0 mL, 16.5 mmol) were added. The mixture was stirred at room temperature overnight and was then diluted with water and methylene chloride. The aqueous layer was made basic with sodium hydroxide (1N), and the layers were separated. The aqueous layer was extracted with methylene chloride. The organic layers were combined, washed with water and brine, dried (Na_2SO_4), filtered, and concentrated to provide a mixture of *N*-methyl benzyl amine and product (3.8 g). The residue was purified with a plug of SiO_2 . The product was recrystallized from hexane and ethyl acetate to provide *N*-benzyl-2-(2-chlorophenothiazin-10-yl)-*N*-methylacetamide as a white solid (258 mg, 40%).

Synthesis of Benzyl-[2-(2-chlorophenothiazin-10-yl)-ethyl]methyl amine fumarate.

[0081] *N*-Benzyl-2-(2-chlorophenothiazin-10-yl)-*N*-methylacetamide (140 mg, 0.355 mmol) was dissolved in THF (5 mL). A solution of borane • THF complex in THF (1.0 M, 5 mL, 5 mmol) was added, and the solution heated to reflux for 4 h. The mixture was carefully diluted with saturated HCl in methanol and stirred for 30 min. The solvent was removed under vacuum, and the residue dissolved in ethyl acetate and aqueous sodium hydroxide (1 N). The layers were separated and the aqueous layer extracted with ethyl acetate. The organic layers were combined, dried (Na_2SO_4), filtered, and concentrated to provide benzyl-[2-(2-chlorophenothiazin-10-yl)-ethyl]methyl amine as a white solid (160 mg). The crude product was purified by SiO_2 chromatography to provide pure product (50 mg, 34%) and 100 mg of impure product. The pure product was dissolved in acetone and a solution of fumaric acid (0.8 mL, 0.02 g/mL in methanol) was added. The solvents were removed under vacuum, and the residue slurried in chloroform and filtered to provide the sub-titled compound (47 mg) as an off-white solid.

Phenothiazine Procedure B

Synthesis of 2-Chloro-10-(1-pyridin-3-ylmethylpiperidin-3-yl)-10*H*-phenothiazine hydrochloride.



Synthesis of 2,4-dichloro-2'-nitrodiphenyl thioether.

[0082] 2,4-Dichlorobenzenethiol (16.1 g, 89.9 mmol) was dissolved in ethanol (200 mL) and was heated to reflux. A solution of sodium acetate (11.1 g, 135 mmol) dissolved in 100 mL ethanol was added, followed by a solution of 1-iodo-2-nitrobenzene (33.6 g, 135 mmol) in ethanol (100 mL, added in small portions over 5 min). The mixture was heated at reflux for 12 h. The mixture was cooled to room temperature and concentrated under vacuum. The residue was dissolved in water and methylene chloride, and the aqueous layer was diluted with saturated sodium bicarbonate. The layers were separated, and the aqueous layer was extracted with methylene chloride. The organic layers were combined, dried (Na_2SO_4), filtered, and concentrated to provide a solid. The residue was washed with 30% ethanol in water (300 mL) and collected by vacuum filtration. The filter cake was rinsed with 30% ethanol in water. The solid was treated with methanol (100 mL), and the product collected by filtration to provide 2,4-dichloro-2'-nitrodiphenyl thioether (25.6 g, 94%) as a yellow solid.

Synthesis of 2,4-dichloro-2'-aminodiphenyl thioether

[0083] 2,4-Dichloro-2'-nitrodiphenyl thioether (22.4 g, 75 mmol) was dissolved in ethyl acetate (125 mL) at 40 °C. Adams catalyst (PtO_2 , 2.5 g) was added, and hydrogen was vigorously bubbled through the solution for 1 h. The mixture was stirred overnight under a static atmosphere of hydrogen. The mixture was cooled to room temperature and filtered through a bed of cellulose. The solvent was removed under vacuum to provide 2,4-dichloro-2'-aminodiphenyl thioether (18.1 g, 89%) as a yellow oil.

Synthesis of 3-Hydroxypiperidine-1-carboxylic acid *tert*-butyl ester

[0084] 3-Hydroxypiperidine (10.0 g, 98.9 mmol) was dissolved in methylene chloride (100 mL) and cooled to 0 °C. Di-*tert*-butyl dicarbonate (27.3 g, 125 mmol) was added at once (copious gas evolution was observed). The mixture was stirred for 12 h at room temperature. The solvent was removed under vacuum to provide 3-hydroxypiperidine-1-carboxylic acid *tert*-butyl ester (19.8 g, 100%).

Synthesis of 3-Oxopiperidine-1-carboxylic acid *tert*-butyl ester.

[0085] A mixture of DMSO (7.8 mL, 109.3 mmol) and methylene chloride (100 mL) was cooled to -78 °C. Oxalyl chloride (4.8 mL, 54.7 mmol) was added to this solution via syringe. The mixture was stirred at -78 °C for 30 min. A solution of 3-hydroxypiperidine-1-carboxylic acid *tert*-butyl ester (10.0 g, 49.7 mmol) in methylene chloride (30 mL) was added dropwise to this solution (temperature remained below -70 °C). The mixture was stirred for 30 min. Triethylamine (28 mL, 200 mmol) was added dropwise over 20 min. The mixture was stirred at -78 °C for 1 h and was allowed to warm to room temperature and stirred for 45 min. The mixture was diluted with water, and the layers separated. The organic layer was washed with water, dried (Na₂SO₄), filtered, and concentrated to give 3-oxopiperidine-1-carboxylic acid *tert*-butyl ester (10.2 g) as a yellow, brown liquid.

Synthesis of 3-[2-(2,4-Dichlorophenylsulfanyl)phenylamino]piperidine-1-carboxylic acid *tert*-butyl ester.

[0086] 2,4-Dichloro-2'-aminodiphenyl thioether (10.3 g, 38.1 mmol) was dissolved in dichloroethane (120 mL). To this solution, a solution of 3-oxopiperidine-1-carboxylic acid *tert*-butyl ester (14.0 g, 70.3 mmol) in dichloroethane (20 mL) and solid sodium triacetoxyborohydride (14.5 g, 68.7 mmol) were slowly added. Acetic acid (5.4 mL, 94 mmol) was added slowly via syringe, and the mixture stirred for 48 h. The mixture was carefully diluted with water, and the pH was adjusted to approximately 9 with aqueous sodium hydroxide (1 N). The mixture was diluted with ethyl acetate, and the layers were separated. The aqueous layer was extracted with ethyl acetate. The organic layers were combined, dried (Na₂SO₄), filtered, and concentrated to provide 3-[2-(2,4-dichlorophenylsulfanyl)phenylamino]piperidine-1-carboxylic acid *tert*-butyl ester

as a brown oil. The crude product was purified by SiO₂ chromatography resulting in pure product (8.4 g, 49%) as a light yellow oil.

Synthesis of 3-(2-Chlorophenothiazin-10-yl)piperidine-1-carboxylic acid *tert*-butyl ester.

[0087] 3-[2-(2,4-Dichlorophenylsulfanyl)phenylamino]piperidine-1-carboxylic acid *tert*-butyl ester (8.4 g, 18.5 mmol) was dissolved in DMF (120 mL) and vigorously degassed with N₂ for 20 min. Cesium carbonate (27.2 g, 83.5 mmol), copper(I) iodide (5.28 g, 27.8 mmol), and copper powder (8.4 g, 132 mmol) were added to the solution. The suspension was stirred vigorously and heated to 155-156 °C for 12 hours (N₂ was continuously bubbled through the mixture). The mixture was cooled to room temperature and diluted with ethyl acetate. The solids were removed by vacuum filtration and were rinsed with ethyl acetate. The filtrate was concentrated under vacuum to remove 90% of the volatiles. The residue was purified by SiO₂ chromatography to provide 3-(2-chlorophenothiazin-10-yl) piperidine-1-carboxylic acid *tert*-butyl ester (4.1 g, 53%) as a white solid.

Synthesis of 2-Chloro-10-piperidin-3-yl-10*H*-phenothiazine hydrochloride

[0088] 3-(2-Chlorophenothiazin-10-yl) piperidine-1-carboxylic acid *tert*-butyl ester (4.1 g, 9.83 mmol) was dissolved in diethyl ether (200 mL), and the solution cooled to 0 °C. A solution of HCl in ethyl acetate (~4 M, 30 mL) was slowly added. The mixture was allowed to warm to room temperature and stirred for 8 h. The solvent was removed under vacuum. The residue treated with HCl in ethyl acetate (~4 M, 75 mL) and stirred overnight. The solvent was removed under vacuum to provide 2-chloro-10-piperidin-3-yl-10*H*-phenothiazine (3.98 g, 100%) as an off-white solid.

Synthesis of 2-Chloro-10-(1-pyridin-3-yl-methylpiperidin-3-yl)-10*H*-phenothiazine hydrochloride.

[0089] Using methods substantially equivalent to those described in the synthesis of 3-[2-(2,4-dichloro-phenylsulfanyl)-phenylamino]-piperidine-1-carboxylic acid *tert*-butyl ester,

[0090] 2-chloro-10-(1-pyridin-3-yl-methyl)piperidin-3-yl)-10*H*-phenothiazine was prepared by treatment of 2-chloro-10-piperidin-3-yl-10*H*-phenothiazine (240 mg, 0.757 mmol) and 3-pyridinecarboxaldehyde (81 mg, 0.757 mmol) with sodium triacetoxyborohydride (224 mg, 1.06 mmol) to provide after treatment with ethereal HCl, the sub-titled compound (136 mg, 41%).

Induction of Mitotic Arrest in Cell Populations Treated with a Phenothiazine KSP Inhibitor

[0091] FACS analysis to determine cell cycle stage by measuring DNA content was performed as follows. Skov-3 cells (human ovarian cancer) were split 1:10 for plating in 10cm dishes and grown to subconfluence with RPMI 1640 medium containing 5% fetal bovine serum (FBS). The cells were then treated with either 10nM paclitaxel, the test compound or 0.25% DMSO (vehicle for compounds) for 24 hours. Cells were then rinsed off the plates with PBS containing 5mM EDTA, pelleted, washed once in PBS containing 1% FCS, and then fixed overnight in 85% ethanol at 4°C. Before analysis, the cells were pelleted, washed once, and stained in a solution of 10µg propidium iodide and 250µg of ribonuclease (RNase) A per milliliter at 37°C for half an hour. Flow cytometry analysis was performed on a Becton-Dickinson FACScan, and data from 10,000 cells per sample was analyzed with Modfit software.

[0092] The phenothiazine compounds, as well as the known anti-mitotic agent paclitaxel, caused a shift in the population of cells from a G0/G1 cell cycle stage (2n DNA content) to a G2/M cell cycle stage (4n DNA content). Other compounds of this class were found to have similar effects.

Monopolar Spindle Formation following Application of a Phenothiazine KSP Inhibitor

[0093] To determine the nature of the G2/M accumulation, human tumor cell lines Skov-3 (ovarian), HeLa (cervical), and A549 (lung) were plated in 96-well plates at densities of 4,000 cells per well (SKOV-3 & HeLa) or 8,000 cells per well (A549),

allowed to adhere for 24 hours, and treated with various concentrations of the phenothiazine compounds for 24 hours. Cells were fixed in 4% formaldehyde and stained with antitubulin antibodies (subsequently recognized using fluorescently-labeled secondary antibody) and Hoechst dye (which stains DNA).

[0094] Visual inspection revealed that the phenothiazine compounds caused cell cycle arrest in the prometaphase stage of mitosis. DNA was condensed and spindle formation had initiated, but arrested cells uniformly displayed monopolar spindles, indicating that there was an inhibition of spindle pole body separation. Microinjection of anti-KSP antibodies also causes mitotic arrest with arrested cells displaying monopolar spindles.

Inhibition of Cellular Proliferation in Tumor Cell Lines Treated with Phenothiazine KSP Inhibitors.

[0095] Cells were plated in 96-well plates at densities from 1000-2500 cells/well of a 96-well plate (depending on the cell line) and allowed to adhere/grow for 24 hours. They were then treated with various concentrations of drug for 48 hours. The time at which compounds are added is considered T_0 . A tetrazolium-based assay using the reagent 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) (LS> Patent No. 5,185,450) (see Promega product catalog #G3580, CellTiter 96® AQueous One Solution Cell Proliferation Assay) was used to determine the number of viable cells at T_0 and the number of cells remaining after 48 hours compound exposure. The number of cells remaining after 48 hours was compared to the number of viable cells at the time of drug addition, allowing for calculation of growth inhibition.

[0096] The growth over 48 hours of cells in control wells that had been treated with vehicle only (0.25% DMSO) is considered 100% growth and the growth of cells in wells with compounds is compared to this. Phenothiazine KSP inhibitors inhibited cell proliferation in human tumor cell lines of the following tumor types: lung (NCI-H460, A549), breast (MDA-MB-231, MCF-7, MCF-7/ADR-RES), colon (HT29, HCT15), ovarian (SKOV-3, OVCAR-3), leukemia (HL-60(TB), K-562), central nervous system (SF-268), renal (A498), osteosarcoma (U2-OS), and cervical (HeLa). In addition, a mouse tumor line (B16, melanoma) was also growth-inhibited in the presence of the phenothiazine compounds.

[0097] A Gi_{50} was calculated by plotting the concentration of compound in μM vs the percentage of cell growth of cell growth in treated wells. The Gi_{50} calculated for the compounds is the estimated concentration at which growth is inhibited by 50% compared to control, i.e., the concentration at which:

$$100 \times [(Treated_{48} - T_0) / (Control_{48} - T_0)] = 50.$$

[0098] All concentrations of compounds are tested in duplicate and controls are averaged over 12 wells. A very similar 96-well plate layout and Gi_{50} calculation scheme is used by the National Cancer Institute (see Monks, et al., J. Natl. Cancer Inst. 83:757-766 (1991)). However, the method by which the National Cancer Institute quantitates cell number does not use MTS, but instead employs alternative methods.

Calculation Of IC_{50} :

[0099] Measurement of a composition's IC_{50} for KSP activity uses an ATPase assay. The following solutions are used: Solution 1 consists of 3 mM phosphoenolpyruvate potassium salt (Sigma P-7127), 2 mM ATP (Sigma A-3377), 1 mM IDTT (Sigma D-9779), 5 μM paclitaxel (Sigma T-7402), 10 ppm antifoam 289 (Sigma A-8436), 25 mM Pipes/KOH pH 6.8 (Sigma P6757), 2 mM $MgCl_2$ (VWR JT400301), and 1 mM EGTA (Sigma E3889). Solution 2 consists of 1 mM NADH (Sigma N8129), 0.2 mg/ml BSA (Sigma A7906), pyruvate kinase 7U/ml, L-lactate dehydrogenase 10 U/ml (Sigma P0294), 100 nM KSP motor domain, 50 $\mu g/ml$ microtubules, 1 mM DTT (Sigma D9779), 5 μM paclitaxel (Sigma T-7402), 10 ppm antifoam 289 (Sigma A-8436), 25 mM Pipes/KOH pH 6.8 (Sigma P6757), 2 mM $MgCl_2$ (VWR JT4003-01), and 1 mM EGTA (Sigma E3889). Serial dilutions (8-12 two-fold dilutions) of the composition are made in a 96-well microtiter plate (Corning Costar 3695) using Solution 1. Following serial dilution each well has 50 μl of Solution 1. The reaction is started by adding 50 μl of solution 2 to each well. This may be done with a multichannel pipettor either manually or with automated liquid handling devices. The microtiter plate is then transferred to a microplate absorbance reader and multiple absorbance readings at 340 nm are taken for each well in a kinetic mode. The observed rate of change, which is proportional to the ATPase rate, is then plotted as a function of the compound concentration. For a standard IC_{50} determination the data acquired is fit by the following four parameter equation using a nonlinear fitting program (e.g., Grafit 4):

$$y = \frac{\text{Range}}{1 + \left(\frac{x}{\text{IC}_{50}} \right)^s} + \text{Background}$$


where y is the observed rate and x the compound concentration.

[00100] The K_i for a compound is determined from the IC_{50} based on three assumptions. First, only one compound molecule binds to the enzyme and there is no cooperativity. Second, the concentrations of active enzyme and the compound tested are known (i.e., there are no significant amounts of impurities or inactive forms in the preparations). Third, the enzymatic rate of the enzyme-inhibitor complex is zero. The rate (i.e., compound concentration) data are fitted to the equation:

$$V = V_{\max} E_0 \left[I - \frac{(E_0 + I_0 + K_d) - \sqrt{(E_0 + I_0 + K_d)^2 - 4 E_0 I_0}}{2 E_0} \right]$$

where V is the observed rate, V_{\max} is the rate of the free enzyme, I_0 is the inhibitor concentration, E_0 is the enzyme concentration, and K_d is the dissociation constant of the enzyme-inhibitor complex.

[00101] Several representative compounds of the invention (as their fumarate salts) were tested as described above and found to exhibit K_i 's less than 10 μM . Their structures are as shown:



[00102] The phenothiazine compounds inhibit growth in a variety of cell lines, including cell lines (MCF-7/ADR-RES, HCT1 5) that express P-glycoprotein (also known as Multi-drug Resistance, or MDR⁺), which conveys resistance to other chemotherapeutic drugs, such as paclitaxel. Therefore, the phenothiazines are anti-mitotics that inhibit cell proliferation, and are not subject to resistance by overexpression of MDR⁺ by drug-resistant tumor lines.


[00103] Compounds of this class were found to inhibit cell proliferation, although GI₅₀ values varied. GI₅₀ values for the phenothiazine compounds tested ranged from 200 nM to greater than the highest concentration tested. By this we mean that although most of the compounds that inhibited KSP activity biochemically did inhibit cell proliferation, for some, at the highest concentration tested (generally about 20 μ M), cell growth was inhibited less than 50%. Many of the compounds have GI₅₀ values less than 10 μ M, and

several have GI_{50} values less than 1 μM . Anti-proliferative compounds that have been successfully applied in the clinic to treatment of cancer (cancer chemotherapeutics) have GI_{50} 's that vary greatly. For example, in A549 cells, paclitaxel GI_{50} is 4 nM, doxorubicin is 63 nM, 5-fluorouracil is 1 μM , and hydroxyurea is 500 μM (data provided by National Cancer Institute, Developmental Therapeutic Program, <http://dtp.nci.nih.gov/>). Therefore, compounds that inhibit cellular proliferation at virtually any concentration may be useful. However, preferably, compounds will have GI_{50} values of less than 1 mM. More preferably, compounds will have GI_{50} values of less than 20 μM . Even more preferably, compounds will have GI_{50} values of less than 10 μM . Further reduction in GI_{50} values may also be desirable, including compounds with GI_{50} values of less than 1 μM .

CLAIMS

We claim:

1. A method of treating cellular proliferative diseases comprising administering a compound of the formula



wherein

R¹ is hydrogen, halogen or CF₃;


R² is chosen from hydrogen and lower alkyl;

R³ is hydrogen;

R⁴ and R⁵ are independently chosen from hydrogen, alkyl, substituted alkyl, alkylaryl, substituted alkylaryl, alkylheteroaryl and substituted alkylheteroaryl; or

any of R², R³ and R⁴ taken together with the intervening atoms form one or more five- to seven-membered rings, said ring optionally substituted with one or more alkyl, aryl, alkoxy, halo, alkylaryl or substituted alkylaryl substituents, with the proviso that said phenothiazine must contain at least one additional five- to seven-membered ring, or a pharmaceutically acceptable salt thereof.

2. A method of treating a disorder associated with KSP kinesin activity comprising administering a compound of formula



wherein

R^1 is hydrogen, halogen or CF_3 ;


R^2 is chosen from hydrogen and lower alkyl;

R^3 is hydrogen;

R^4 and R^5 are independently chosen from hydrogen, alkyl, substituted alkyl, alkylaryl, substituted alkylaryl, alkylheteroaryl and substituted alkylheteroaryl; or

any of R^2 , R^3 and R^4 taken together with the intervening atoms form one or more five- to seven-membered rings, said ring optionally substituted with one or more alkyl, aryl, alkoxy, halo, alkylaryl or substituted alkylaryl substituents, with the proviso that said phenothiazine must contain at least one additional five- to seven-membered ring, or a pharmaceutically acceptable salt thereof.

3. A method of inhibiting KSP kinesin comprising contacting KSP kinesin with a compound of formula



wherein

R^1 is hydrogen, halogen or CF_3 ;

R^2 is chosen from hydrogen and lower alkyl;


R^3 is hydrogen;

R^4 and R^5 are independently chosen from hydrogen, alkyl, substituted alkyl, alkylaryl, substituted alkylaryl, alkylheteroaryl and substituted alkylheteroaryl; or

any of R^2 , R^3 and R^4 taken together with the intervening atoms form one or more five- to seven-membered rings, said ring optionally substituted with one or more alkyl, aryl, alkoxy, halo, alkylaryl or substituted alkylaryl substituents, with the proviso that said phenothiazine must contain at least one additional five- to seven-membered ring, or a pharmaceutically acceptable salt thereof.

4. A method according to claim 1, 2 or 3 wherein wherein R^3 is hydrogen and R^2 and R^4 form a five- to seven-membered ring.


5. A method according to claim 4 wherein said phenothiazine has the formula



6. A method according to claim 1, 2 or 3 wherein R^2 and R^3 are hydrogen and R^5 is alkylaryl or substituted alkylaryl.

7. A method according to claim 1 or 2 wherein said disease or disorder is chosen from the group consisting of cancer, hyperplasia, restenosis, cardiac hypertrophy, immune disorders and inflammation.

8. A method according to claim 4 wherein said disease or disorder is chosen from the group consisting of cancer, hyperplasia, restenosis, cardiac hypertrophy, immune disorders and inflammation.
9. A method according to claim 5 wherein said disease or disorder is chosen from the group consisting of cancer, hyperplasia, restenosis, cardiac hypertrophy, immune disorders and inflammation.
10. A method according to claim 6 wherein said disease or disorder is chosen from the group consisting of cancer, hyperplasia, restenosis, cardiac hypertrophy, immune disorders and inflammation.
11. A phenothiazine of the formula



wherein

R^1 is hydrogen, halogen or CF_3 ;

R^2 is chosen from hydrogen and lower alkyl;

R^3 is hydrogen;

R^{4a} is chosen from hydrogen and lower alkyl; and


R^{5a} is chosen from alkylaryl, substituted alkylaryl, alkylheteroaryl and substituted alkylheteroaryl; or

any of R^2 , R^3 and R^{4a} taken together with the intervening atoms form one or more five- to seven-membered rings, said ring optionally substituted with one or more alkyl, aryl,

alkoxy, halo, alkylaryl or substituted alkylaryl substituents, or a pharmaceutically acceptable salt thereof.

12. A phenothiazine according to claim 11 wherein R^3 is hydrogen and R^2 and R^{4a} form a five- to seven-membered ring.

13. A phenothiazine according to claim 12 of formula




14. A phenothiazine according to claim 13 wherein R^{5a} is benzyl or substituted benzyl.

15. A phenothiazine according to claim 11 wherein R^2 and R^3 are hydrogen and R^{5a} is alkylaryl or substituted alkylaryl.

16. A phenothiazine according to claim 15 wherein R^{5a} is benzyl or substituted benzyl.

17. A method of screening for KSP kinesin modulators comprising:
combining a kinesin, a candidate bioactive agent and a compound of the formula



wherein

R^1 is hydrogen, halogen or CF_3 ;

R^2 is chosen from hydrogen and lower alkyl;


R^3 is hydrogen;

R^4 and R^5 are independently chosen from hydrogen, alkyl, substituted alkyl, alkylaryl, substituted alkylaryl, alkylheteroaryl and substituted alkylheteroaryl; or

any of R^2 , R^3 and R^4 taken together with the intervening atoms form one or more five- to seven-membered rings, said ring optionally substituted with one or more alkyl, aryl, alkoxy, halo, alkylaryl or substituted alkylaryl substituents, with the proviso that said phenothiazine must contain at least one additional five- to seven-membered ring, , or a pharmaceutically acceptable salt thereof, and

determining the effect of said candidate bioactive agent on the activity of said kinesin.

18. A method of screening for compounds that bind to KSP kinesin comprising:
combining a kinesin, a candidate bioactive agent and a labeled compound of the formula



wherein

R^1 is hydrogen, halogen or CF_3 ;

R^2 is chosen from hydrogen and lower alkyl;

R^3 is hydrogen;

R^4 and R^5 are independently chosen from hydrogen, alkyl, substituted alkyl, alkylaryl, substituted alkylaryl, alkylheteroaryl and substituted alkylheteroaryl; or

any of R^2 , R^3 and R^4 taken together with the intervening atoms form one or more five- to seven-membered rings, said ring optionally substituted with one or more alkyl, aryl, alkoxy, halo, alkylaryl or substituted alkylaryl substituents, with the proviso that said phenothiazine must contain at least one additional five- to seven-membered ring, or a pharmaceutically acceptable salt thereof; and

determining the binding of said candidate bioactive agent to said kinesin.

INTERNATIONAL SEARCH REPORT

International Application No

PLT/US 02/01710

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D279/28 C07D279/26 C07D417/04 C07D417/14 A61K31/5415
A61P35/00 A61P37/02

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BEILSTEIN Data, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2 784 185 A (ALFONS SCHULER WILHELM) 5 March 1957 (1957-03-05) the whole document, especially column 1, lines 1-45	1,11-16
X	US 2 830 987 A (GAILLOT P. ET AL) 15 April 1958 (1958-04-15) column 1; example 2	1,11,14
A	US 2 901 478 A (ALFONS SCHULER WILHELM) 25 August 1959 (1959-08-25) the whole document	1,11
A	EP 0 346 239 A (RHONE POULENC SANTE) 13 December 1989 (1989-12-13) claims	1,11
-/-		

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *Z* document member of the same patent family

Date of the actual completion of the international search

26 April 2002

Date of mailing of the international search report

10/05/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Chouly, J

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 02/01710

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,A	WO 01 98278 A (BERGNES GUSTAV ;CHABALA JOHN C (US); FENG BAINIAN (US); FINER JEFF) 27 December 2001 (2001-12-27) claims	1,11
P,A	WO 01 30768 A (BERGNES GUSTAVE ;CHABALA JOHN C (US); FENG BAINIAN (US); FINER JEF) 3 May 2001 (2001-05-03) claims	1,11

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 02/01710

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 2784185	A	05-03-1957	FR 1159125 A GB 772179 A	23-06-1958 10-04-1957
US 2830987	A		NONE	
US 2901478	A	25-08-1959	NONE	
EP 0346239	A	13-12-1989	FR 2632521 A1 AT 90085 T AU 621121 B2 AU 3624189 A CA 1323027 A1 DE 68906826 D1 DE 68906826 T2 DK 283289 A EP 0346239 A1 ES 2057160 T3 HU 51607 A2 IE 61601 B IL 90560 A JP 2032070 A PT 90814 A ,B US 4985419 A ZA 8904401 A	15-12-1989 15-06-1993 05-03-1992 21-12-1989 12-10-1993 08-07-1993 30-09-1993 11-12-1989 13-12-1989 16-10-1994 28-05-1990 16-11-1994 31-08-1995 01-02-1990 29-12-1989 15-01-1991 28-02-1990
WO 0198278	A	27-12-2001	AU 1439801 A WO 0130768 A1 WO 0198278 A1	08-05-2001 03-05-2001 27-12-2001
WO 0130768	A	03-05-2001	AU 1439801 A WO 0130768 A1 WO 0198278 A1	08-05-2001 03-05-2001 27-12-2001

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:



BLACK BORDERS

☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**

☐ **FADED TEXT OR DRAWING**

☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**

☐ **SKEWED/SLANTED IMAGES**

☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**

☐ **GRAY SCALE DOCUMENTS**



☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**

☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**

☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.